MX9702553A - Adenovirus libres de particulas contaminantes viables, su preparacion y su uso. - Google Patents

Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.

Info

Publication number
MX9702553A
MX9702553A MX9702553A MX9702553A MX9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A
Authority
MX
Mexico
Prior art keywords
preparation
particle free
contaminant particle
viable
disclosed
Prior art date
Application number
MX9702553A
Other languages
English (en)
Inventor
Patrice Yeh
Michel Perricaudet
Cecile Orsini
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9702553A publication Critical patent/MX9702553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con vectores virales novedosos, derivados de adenovirus, su preparacion y su utilizacion en terapia genética. Se relaciona de manera preferible, con los adenovirus recombinantes que comprenden un genoma de un adenovirus (i) en el que la region E1 está inactivada, (ii) en el que la organizacion genomica está modificada (iii) en el que la recombinacion eventual con el genoma del linaje de produccion conduce a la generacion de partículas virales no viables.
MX9702553A 1994-10-28 1995-10-25 Adenovirus libres de particulas contaminantes viables, su preparacion y su uso. MX9702553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413355A FR2726285B1 (fr) 1994-10-28 1994-10-28 Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
PCT/FR1995/001415 WO1996013596A1 (fr) 1994-10-28 1995-10-25 Adenovirus depourvus de particules contaminantes viables, preparation et utilisations

Publications (1)

Publication Number Publication Date
MX9702553A true MX9702553A (es) 1997-06-28

Family

ID=9468601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702553A MX9702553A (es) 1994-10-28 1995-10-25 Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.

Country Status (13)

Country Link
US (2) US6312946B1 (es)
EP (1) EP0787199A1 (es)
JP (1) JPH10507922A (es)
KR (1) KR100424803B1 (es)
CN (1) CN1110564C (es)
AU (1) AU703539B2 (es)
FI (1) FI971783A (es)
FR (1) FR2726285B1 (es)
IL (1) IL115779A0 (es)
MX (1) MX9702553A (es)
NO (1) NO320090B1 (es)
WO (1) WO1996013596A1 (es)
ZA (1) ZA959086B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
DK0787200T3 (da) * 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
AU709498B2 (en) * 1994-12-12 1999-09-02 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
EP0951553B1 (en) * 1996-07-05 2003-10-29 Philip E. Branton Adenovirus e4 proteins for inducing cell death
US6730662B1 (en) 1996-07-05 2004-05-04 Mcgill University Adenovirus E4 proteins for inducing cell death
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6638502B1 (en) 1997-04-28 2003-10-28 Gencell Sas Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
ES2180258T3 (es) * 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
US6461869B1 (en) * 1999-07-20 2002-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Purging leukemia cells from hematopoietic stem cells
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
KR101250021B1 (ko) * 2000-05-26 2013-04-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2006060089A2 (en) * 2004-10-25 2006-06-08 Biogen Idec Ma Inc. Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations
BRPI0714981A2 (pt) * 2006-07-28 2013-08-13 Sanofi Aventis composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
AU2011292119B2 (en) * 2010-08-16 2015-06-11 Salk Institute For Biological Studies Anti-cancer adenoviruses
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
AU2019205330A1 (en) 2018-01-04 2020-08-27 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
KR20220106072A (ko) * 2021-01-21 2022-07-28 주식회사 셀리드 복제가능 아데노바이러스를 포함하지 않는 신규 아데노바이러스 벡터 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy

Also Published As

Publication number Publication date
FR2726285A1 (fr) 1996-05-03
JPH10507922A (ja) 1998-08-04
NO971764L (no) 1997-04-17
WO1996013596A1 (fr) 1996-05-09
EP0787199A1 (fr) 1997-08-06
FR2726285B1 (fr) 1996-11-29
CN1110564C (zh) 2003-06-04
US6312946B1 (en) 2001-11-06
NO320090B1 (no) 2005-10-24
NO971764D0 (no) 1997-04-17
KR100424803B1 (ko) 2004-06-12
CN1162338A (zh) 1997-10-15
KR970707292A (ko) 1997-12-01
US20010039046A1 (en) 2001-11-08
ZA959086B (en) 1996-07-16
AU3847795A (en) 1996-05-23
AU703539B2 (en) 1999-03-25
US6482617B2 (en) 2002-11-19
FI971783A0 (fi) 1997-04-25
FI971783A (fi) 1997-04-25
IL115779A0 (en) 1996-01-19

Similar Documents

Publication Publication Date Title
MX9702553A (es) Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.
CZ63995A3 (en) Virus vectors and their use in gene therapy
CA2236968A1 (en) Accessory functions for use in recombinant aav virion production
AU5152998A (en) Improved adenovirus vectors
CA2161962A1 (en) Adenovirus vectors for gene therapy
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
AU7335296A (en) Recombinant sendai virus
ES2168258T3 (es) Vectores virales recombinantes que codifican para proteinas de papilomavirus humano.
AU681705B2 (en) Endosomolytically active particles
AU2853395A (en) Recombinant vectors derived from adenovirus for use in gene therapy
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
AUPN477695A0 (en) Gene therapy
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
NZ331556A (en) Parapoxviruses containing foreign DNA, their production and their use in vaccines
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
AU4307197A (en) Herpesvirus saimiri as viral vector
AU3525095A (en) Deffective recombinant adenoviruses with inactivated iva2 gene
ATE46264T1 (de) Thymidinkinase-negativ-temperaturbestaendiger rinder herpes-virus-1-mutant als vakzin gegen infektioese rinder-rhinotracheitis.
MX9700870A (es) Virus de herpes recombinante con promotor de gen gb.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees